Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy

Cancer Immunology, Immunotherapy

Volumn 65, Issue 7, 2016, Pages 857-867

  Baniyash, Michal ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cancer; Chemotherapy; Chronic inflammation; CITIM 2015; Immune system biomarkers; Immunotherapy

Indexed keywords

ANIMAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; IMMUNOTHERAPY; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84969919923     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1849-y     Document Type: Review

References (50)

1. Baniyash M, Sade-Feldman M, Kanterman J (2014) Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother 63(1):11–20. doi:10.1007/s00262-013-1468-9
2. Talmadge JE, Gabrilovich DI (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer 13(10):739–752. doi:10.1038/nrc3581
3. Ezernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E, Halabi A et al (2006) TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 177(7):4763–4772. doi:10.4049/jimmunol.177.7.4763
4. Kanterman J, Sade-Feldman M, Baniyash M (2012) New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 22(4):307–318. doi:10.1016/j.semcancer.2012.02.008
5. Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M (2013) Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38(3):541–554. doi:10.1016/j.immuni.2013.02.007
6. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P (2012) PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest 41(6–7):635–657. doi:10.3109/08820139.2012.695417
7. Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z et al (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252(1):86–92. doi:10.1016/j.canlet.2006.12.012
8. Yang WC, Ma G, Chen SH, Pan PY (2013) Polarization and reprogramming of myeloid-derived suppressor cells. J Mol Cell Biol 5(3):207–209. doi:10.1093/jmcb/mjt009
9. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. doi:10.1038/nri2506
10. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499–4506. doi:10.4049/jimmunol.0802740
11. Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W et al (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108(41):17111–17116. doi:10.1073/pnas.1108121108
12. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI (2010) Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 184(6):3106–3116. doi:10.4049/jimmunol.0902661
13. Baniyash M (2004) TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 4(9):675–687. doi:10.1038/nri1434
14. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC (2002) Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 277(24):21123–21129. doi:10.1074/jbc.M110675200
15. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70(1):68–77. doi:10.1158/0008-5472.CAN-09-2587
16. Schmielau J, Nalesnik MA, Finn OJ (2001) Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 7(3 Suppl):933s–939s
17. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P et al (2002) Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 168(2):689–695. doi:10.4049/jimmunol.168.2.689
18. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D et al (2011) Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 208(10):1949–1962. doi:10.1084/jem.20101956
19. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED et al (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6(5):1755–1766
20. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10(1):48–54. doi:10.1038/nm976
21. Crook KR, Jin M, Weeks MF, Rampersad RR, Baldi RM, Glekas AS et al (2015) Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. J Leukoc Biol 97(3):573–582. doi:10.1189/jlb.4A0314-139R
22. Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X (2009) Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 182(6):3801–3808. doi:10.4049/jimmunol.0801548
23. Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140(6):1807–1816. doi:10.1053/j.gastro.2011.01.057
24. Kidane D, Murphy DL, Sweasy JB (2014) Accumulation of abasic sites induces genomic instability in normal human gastric epithelial cells during Helicobacter pylori infection. Oncogenesis 3:e128. doi:10.1038/oncsis.2014.42
25. Chiba T, Marusawa H, Ushijima T (2012) Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 143(3):550–563. doi:10.1053/j.gastro.2012.07.009
26. Ma Y, Han W, Yang L, He L, Wang H (2015) The regulation of miRNAs in inflammation-related carcinogenesis. Curr Pharm Des 21(21):3023–3031. doi:10.2174/1381612821666150514105606#sthash.8nPnrzyJ.dpuf
27. Katoh H, Watanabe M (2015) Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediat Inflamm 2015:159269. doi:10.1155/2015/159269
28. Sceneay J, Parker BS, Smyth MJ, Moller A (2013) Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. Oncoimmunology 2(1):e22355. doi:10.4161/onci.22355
29. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y et al (2004) Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6(4):409–421. doi:10.1016/j.ccr.2004.08.031
30. Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S et al (2010) Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci USA 107(29):13063–13068. doi:10.1073/pnas.1002372107
31. Mauti LA, Le Bitoux MA, Baumer K, Stehle JC, Golshayan D, Provero P et al (2011) Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J Clin Invest 121(7):2794–2807. doi:10.1172/JCI41936
32. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA et al (2013) Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol 15(7):891–903. doi:10.1093/neuonc/not031
33. Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A et al (2014) Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res 74(21):6022–6035. doi:10.1158/0008-5472.CAN-14-0657
34. Maru GB, Gandhi K, Ramchandani A, Kumar G (2014) The role of inflammation in skin cancer. Adv Exp Med Biol 816:437–469. doi:10.1007/978-3-0348-0837-8_17
35. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K et al (2015) Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 21(24):5453–5459. doi:10.1158/1078-0432.CCR-15-0676
36. Kitano S, Postow MA, Ziegler CG, Kuk D, Panageas KS, Cortez C et al (2014) Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res 2(8):812–821. doi:10.1158/2326-6066.CIR-14-0013
37. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532. doi:10.1056/NEJMoa1503093
38. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017. doi:10.1056/NEJMoa1414428
39. Makalowski J, Abken H (2013) Adoptive cell therapy of melanoma: the challenges of targeting the beating heart, Melanoma - From Early Detection to Treatment. Dr Ht Duc (Ed), ISBN: 978-953-51-0961-7, InTech. www.intechopen.com/books/melanoma-from-early-detection-to-treatment/adoptive-cell-therapy-of-melanoma-the-challenges-of-targeting-the-beating-heart. Accessed January 30, 2013. doi:10.5772/53619
40. Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L et al (2013) Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol 133(6):1610–1619. doi:10.1038/jid.2012.444
41. Boniface JD, Poschke I, Mao Y, Kiessling R (2012) Tumor-dependent down-regulation of the zeta-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 131(1):129–139. doi:10.1002/ijc.26355
42. Draghiciu O, Lubbers J, Nijman HW, Daemen T (2015) Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology 4(1):e954829. doi:10.4161/21624011.2014.954829
43. Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S et al (2013) Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol 59(5):1007–1013. doi:10.1016/j.jhep.2013.06.010
44. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA et al (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312(17):1744–1753. doi:10.1001/jama.2014.13943
45. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG et al (2010) COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 10:464. doi:10.1186/1471-2407-10-464
46. Kusmartsev S, Eruslanov E, Kubler H, Tseng T, Sakai Y, Su Z et al (2008) Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 181(1):346–353. doi:10.4049/jimmunol.181.1.346
47. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P et al (2005) Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 102(11):4185–4190. doi:10.1073/pnas.0409783102
48. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T et al (2012) Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep 2(3):628–639. doi:10.1016/j.celrep.2012.08.006
49. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ et al (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66(18):9299–9307. doi:10.1158/0008-5472.CAN-06-1690
50. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D (2013) Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 62(5):909–918. doi:10.1007/s00262-013-1396-8